FY2027 EPS Estimates for AC Immune Lifted by Leerink Partnrs

AC Immune (NASDAQ:ACIU - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for shares of AC Immune in a research report issued to clients and investors on Friday, July 11th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $0.13 per share for the year, up from their previous forecast of $0.10. The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share.

Several other equities research analysts have also issued reports on the company. Wall Street Zen raised AC Immune from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th. HC Wainwright lowered their target price on AC Immune from $16.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, May 1st.

AC Immune Stock Up 2.0%

Shares of ACIU traded up $0.04 during trading on Monday, reaching $2.08. The company's stock had a trading volume of 51,037 shares, compared to its average volume of 158,448. The company has a fifty day moving average of $1.86 and a two-hundred day moving average of $2.13. AC Immune has a twelve month low of $1.43 and a twelve month high of $4.26. The company has a market cap of $208.85 million, a price-to-earnings ratio of -3.59 and a beta of 1.62.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The business had revenue of $1.12 million during the quarter, compared to analysts' expectations of $1.99 million. AC Immune had a negative return on equity of 44.60% and a negative net margin of 177.79%.

Institutional Investors Weigh In On AC Immune

Several institutional investors have recently made changes to their positions in the company. Quinn Opportunity Partners LLC acquired a new position in shares of AC Immune during the fourth quarter worth approximately $27,000. Two Sigma Advisers LP bought a new stake in shares of AC Immune during the fourth quarter worth $36,000. Boothbay Fund Management LLC bought a new stake in shares of AC Immune during the fourth quarter worth $38,000. Banque Cantonale Vaudoise acquired a new position in shares of AC Immune during the first quarter valued at $50,000. Finally, RPO LLC acquired a new position in AC Immune in the fourth quarter valued at about $51,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.